"This is an important milestone for Mobius Therapeutics, and we are very pleased that CMS has issued a J-code for Mitosol®," said Ed Timm, Chief Executive Officer and Founder of Mobius Therapeutics, LLC. "While it may take up to three months for the J-code to be loaded into the entire payer system, the J-code facilitates more rapid reimbursement for providers. Mitosol is manufactured under cGMP controls and provides assured dosing concentration with consistent potency and sterility. In light of the on-going concerns related to the sterility and quality assurance of sterile filled medications, Mitosol’s quality manufacturing and convenience helps providers and patients with peace of mind.”
J-codes are part of the Healthcare Common Procedure Coding System (HCPCS), and used by providers to identify medical products to facilitate reimbursement.
About Mobius Therapeutics, LLC:
Mobius Therapeutics is a commercial stage venture focused on ophthalmic surgery solutions. Its first product, Mitosol®, is a system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery. The glaucoma indication is in active commercialization;
